SGMT
Sagimet Biosciences Inc. Series A
9.10$
-12.6%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -6.0% | +101.1% | -2.8% | -7.5% | -8.3% | -8.8% | -6.0% | -6.6% | -9.3% | -7.5% | +144.5% | |
| – | -6.0% | +101.2% | -14.3% | -5.7% | -2.8% | -4.4% | -12.9% | -6.3% | -2.4% | -7.5% | +126.5% | |
| – | -26.2% | +135.3% | -45.7% | -19.7% | -1.5% | -14.7% | -34.6% | -23.2% | +7.8% | +4.6% | +352.9% | |
| – | -6.8% | +104.1% | -14.1% | -8.3% | -0.8% | -4.4% | -13.3% | -6.9% | -3.1% | -7.6% | +129.7% | |
| – | +12.0% | -20.2% | +27.0% | -28.6% | +8.8% | +61.2% | +0.9% | +26.2% | -44.2% | +3.8% | +37.3% | |
| – | +12.0% | -20.2% | +27.0% | -28.6% | +8.8% | +61.2% | +0.9% | +26.2% | -44.2% | +3.8% | +2.3% | |
| – | -36.9% | -60.0% | +488.5% | -24.2% | -32.8% | -50.0% | +289.7% | -24.3% | -32.2% | -50.0% | +115.4% | |
| – | -89.1% | +185.5% | +275.5% | -42.2% | +23.7% | +126.2% | -40.4% | +120.9% | -69.1% | +75.9% | -50.9% | |
| – | -7.0% | +108.7% | -3.5% | -6.9% | -8.7% | -10.8% | -6.4% | -8.4% | -6.6% | -8.0% | +150.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +59.6% | +9.9% | +0.7% | +0.2% | +0.0% | +0.0% | +0.8% | +0.2% | +0.1% | +63.1% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.